Economic perspectives for effective control of diabetes mellitus type 2 with fixed combination of basal insulin analog and GLP-1 agonist
Fixed antidiabetic drugs' combinations have aim to improve Diabetes Mellitus type 2 (DMT2) control as well as a safety treatment increasing. Soliqua SoloStar® is a new registered drug for control fasting and prandial glucose levels, contained insulin glargine 100 Ul/ml and lixisenatide. In the...
Saved in:
Main Authors: | S. K. Zyryanov (Author), I. N. Dyakov (Author) |
---|---|
Format: | Book |
Published: |
Izdatelstvo OKI,
2019-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The pharmacoeconomic comparison of the fixed insulin glargine and lixisenatide combination with insulin degludec family in type 2 diabetes mellitus
by: I. N. Dyakov, et al.
Published: (2021) -
Pharmacoeconomic comparison of insulin glargine and insulin detemir in diabetes mellitus type 2
by: I. N. Dyakov, et al.
Published: (2020) -
Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base
by: I. N. Dyakov, et al.
Published: (2021) -
Economic evaluation of the fixed combination of insulin glargine and lixisenatide in Diabetes Mellitus type 2
by: S. V. Nedogoda, et al.
Published: (2020) -
Health technology assessement of the fxed combination of insulin glargine 100 UI/ml and lixisenatide in the treatment intensifcation of diabetes mellitus type 2
by: S. К. Zyryanov, et al.
Published: (2019)